

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for November 2023

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

| Manufacturer | Product | Reference Product | Generic Name | Strength | Dosage Form | DIN |
|---------------------------|-------------------|--------------------------|---------------------|---------------------------|---------------------|------------|
| Mint Pharmaceuticals Inc. | Mint-Tizanidine | Zanaflex | TIZANIDINE HCl | 4 mg | tablet | 02536765 |
| Sandoz Canada Inc. | Sandoz Apremilast | Otezla | APREMILAST | 10 mg/ 20 mg/ 30 mg | tablet-blister pack | 02529092 |